| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 0.03 | 97.5% |
| Total Income | 0.03 | 97.5% |
| Expenditure | 7.63 | 42.8% |
| PBT | — | |
| Net Profit | -7.24 | 34.4% |
| OPM | — | |
| NPM | — | |
| EPS | -4.31 | 1386.2% |
Bolt Biotherapeutics Reports Q1 2026 Financial Results
13 May 2026 · 13 May, 1:42 am
Summary
Bolt Biotherapeutics reported financial results for the first quarter ended March 31, 2026. The company's cash balance was $23.9 million as of March 31, 2026, expected to fund operations into 2027. Collaboration revenue decreased to $26,000 compared to $1.2 million in the same quarter of the previous year. Research and Development expenses decreased to $4.8 million from $9.5 million year-over-year, and General and Administrative expenses decreased to $2.8 million from $3.8 million year-over-year.
Key Highlights
- 1
Bolt Biotherapeutics reported a cash balance of $23.9 million as of March 31, 2026, which is anticipated to fund operations into 2027.
- 2
Collaboration revenue totaled $26,000 for the quarter ended March 31, 2026, compared to $1.2 million for the same quarter in 2025.
- 3
Research and Development expenses decreased to $4.8 million for the quarter ended March 31, 2026, from $9.5 million for the same quarter in 2025.
- 4
General and Administrative expenses were $2.8 million for the quarter ended March 31, 2026, compared to $3.8 million for the same quarter in 2025.
- 5
The loss from operations was $7.6 million for the quarter ended March 31, 2026, compared to $12.1 million for the same quarter in 2025.
Management Comments
Willie Quinn
We are encouraged by what we have seen thus far in patients treated with BDC‑4182, a next‑generation Boltbody™ ISAC. BDC-4182 has a unique mechanism of action , that has the potential to combine the power of ADCs with the durability of T-cell engagers and unlock a new frontier in cancer treatment. We continue to enroll patients with gastric and gastroesophageal cancer in our ongoing clinical trial, and we look forward to reporting initial data in the third quarter of 2026.
Informational and educational content only. Not investment advice.